AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02414555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Study NCT02414555 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: arterial cannulation
Study NCT02414555 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous peripheral line insertion (17 gauge)
Description: for fluid bolus administration
Study NCT02414555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elo-Mel Isoton (balanced acetat-based infusate)
Study NCT02053064 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SAF-301
Study NCT04069429 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computerized Tomography scan
Description: imaging scan from a person's eyes to their thighs
Study NCT02934477 — intervention group
Intervention type: OTHER
Intervention: Hematopoietic Stem Cell Transplant
Description: This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of age-matched non-HCT controls.
Study NCT00845871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox:
Description: Participants were administered daily with deferasirox starting dose of 20 mg/kg orally to a maximum dose of 40 mg/kg/day.
Study NCT00749801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nattokinase
Description: 2 capsules in the morning and before bed-time daily
Study NCT00749801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nattokinase
Description: 2 capsules in the morning and before bed-time daily
Study NCT00749801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nattokinase
Description: 2 capsules in the morning and before bed-time daily
Study NCT04959149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirTraq videolaryngoscope
Description: intubation of morbidly obese patient using Airtraq videolaryngoscope
Study NCT04959149 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirTraq videolaryngoscope
Description: intubation of morbidly obese patient using Airtraq videolaryngoscope
Study NCT02862041 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Echogenic needle - Pajunk sonoplex echogenic needle
Description: Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries
Study NCT02862041 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non Echogenic needle - Stimuplex Braun Nonechogenic needle
Description: Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries
Study NCT01664936 — intervention group
Intervention type: RADIATION
Intervention: Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I
Description: We will image (i) patients who are receiving a PET/CT scan for tumors in the head / neck region and (ii) patients with thyroid cancer after 131I radioablation. Two scans will be completed per patient, one of the primary tumors, as well as a 'background' scan of the contralateral side or, if tumor is there as well, of the forearm. The device to be used is an intensified charge-coupled device camera (Stanford Photonics, Palo Alto, CA) connected to a laptop PC. The camera will use a Quartz high-UV transmission 50 mm 0.8f lens. The Imaging device will be placed approximately 5 cm from the area of the patient to be imaged.
Study NCT02559609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management for alcohol abstinence
Description: Participants will earn reinforcement (incentives) for each alcohol negative breath test provided (when prompted to submit a test) during the 12-week intervention period.
Study NCT02559609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management for completing job related activities
Description: Participants will earn reinforcement (incentives) for completing specific job-related activities during the 12-week intervention period.
Study NCT02559609 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Job relelated activity contracting
Description: Participants will complete job-related activity contracts each week with the goal of obtaining employment.
Study NCT02559609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Job relelated activity contracting
Description: Participants will complete job-related activity contracts each week with the goal of obtaining employment.
Study NCT04376294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy(ESWT)
Description: Each session of Extracorporeal Shockwave Therapy(ESWT) consists of 2000 pulses with a pressure of 3 bars (equals an energy flux density of 0.1 mJ/mm²), and treatment frequency of 8 pulses/sec
Study NCT04376294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric training of the calf muscle:
Description: The patients were asked to stand with all their body weight on the injured leg on a wooden step. From an upright body position and standing with all body weight on the forefoot, with the ankle joint in plantar flexion. The calf muscle is loaded by having the patient lower the affected limb down by dorsiflexion the ankle until the plantar aspect of the heel lay below the level of the step, and the ankle is in maximum dorsiflexion.
Study NCT04376294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric training of the calf muscle:
Description: The patients were asked to stand with all their body weight on the injured leg on a wooden step. From an upright body position and standing with all body weight on the forefoot, with the ankle joint in plantar flexion. The calf muscle is loaded by having the patient lower the affected limb down by dorsiflexion the ankle until the plantar aspect of the heel lay below the level of the step, and the ankle is in maximum dorsiflexion.
Study NCT04376294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gastrocnemius, soleus, and hamstring stretch
Description: Stretching every muscle for 30 seconds. Each stretch was performed 3 times (holding for 30 seconds and rest for 30 seconds). All these stretches were performed directly after the eccentric exercises twice/day for 7 days/week for weeks
Study NCT04376294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastrocnemius, soleus, and hamstring stretch
Description: Stretching every muscle for 30 seconds. Each stretch was performed 3 times (holding for 30 seconds and rest for 30 seconds). All these stretches were performed directly after the eccentric exercises twice/day for 7 days/week for weeks
Study NCT04756011 — intervention group
Intervention type: OTHER
Intervention: Health related quality of life
Description: Confidence in diabetes self care questionnaire the socioeconomic level of the family scale MINI-KID the Peds-QL
Study NCT02718534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stroke rehabilitation
Description: Physical rehabilitation exercise between 24 and 48 hours and after 48 hours
Study NCT02718534 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stroke rehabilitation
Description: Physical rehabilitation exercise between 24 and 48 hours and after 48 hours
Study NCT03112200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subchondroplasty with Arthroscopy
Description: The Subchondroplasty® (SCP®) Procedure targets and fills bone defects with AccuFill® Bone Substitute Material utilizing an arthroscopic / percutaneous approach. Using intraoperative fluoroscopy, the bone defect is localized relative to MRI findings The appropriate AccuPort® Delivery Cannula is drilled to the bone defect. AccuFill® Bone Substitute Material is then injected into the subchondral bone defect. The calcium phosphate (CaP) fills the edematous void and hardens within the Bone Marrow Lesion. The CaP is resorbed over time and replaced with new bone during the healing process.
Study NCT03112200 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Arthroscopy Alone
Description: An endoscopic examination, therapy and surgery of the knee joint.
Study NCT00354133 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinetra and Soletra (neurostimulator, Medtronic)
Description: Patients in this arm were implanted with a neurostimulator (Kinetra and Soletra from Medtronic) are stimulated. Additionally the get best medical treatment.
Study NCT00354133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Treatment
Description: Patients in this arm get best medical treatment only
Study NCT03240341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Activation Measure Questionnaire
Description: Measure the level of patient engagement in cancer care pathway
Study NCT01209481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional education group action
Description: The educational group activities will consist of two-hour group dynamics and cooking workshops once a week and for five weeks.
Study NCT03313115 — intervention group
Intervention type: BEHAVIORAL
Intervention: Sleep/Wake Protocol
Description: Day RN observes if completed per pt: no caffeine after 3 pm, encourage activities to prevent napping (chart % day spent napping), Lights on blinds/door open, Reasonable effort for some noise in room, Eye glasses hearing aids applied, Chair position/mobility at least 2x30 minutes.~Night RN observe if completed per pt: Appropriate pain control, Optimize room temp, Warm bath before 2200, TV off by 2200, Prevent extra alarms after 2200, Close room curtain by 2200, Dim room lights by 2200, Family out by 2200, Door half/fully closed after 2200, # RN interruptions after 2200, Offer eye mask/ear plugs, Meds administered for sleep (dilaudid, fentanyl oxycodone, haldol, quetiapine, propofol, melatonin, or other), Dim hallway lights by 2200, Nurses station quiet
Study NCT03161119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided embryotransfer with Cook K-Jets-551910-S
Description: On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias.
Study NCT03161119 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided embryotransfer with Cook k-soft-5000 (or K-J-SP-681710 and K-J-SPPE-681710)
Description: On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias.
Study NCT02181972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gingko biloba
Study NCT02181972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04370743 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03746977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein
Description: Protein supplementation 1.2 or 1.5 g/kg body mass/d
Study NCT03746977 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: Walking with a volume corresponding to 250 kcal/d
Study NCT03746977 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WB-EMS application
Description: WB-EMS application 1.5x 20 min/week
Study NCT03050437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin is added to Pem/cis arm
Study NCT03050437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pem is applied to both arms
Study NCT03050437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pem is applied to both arms
Study NCT02150265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART manual cognitive behavioral therapy
Study NCT04069429 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography scans
Description: imaging scan taken during, and after, the administration of the radioactive agent
Study NCT04069429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Tc 99M
Description: subjects are administered radioactive heparin as part of study participation.
Study NCT04069429 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Planar Images
Description: 2 dimensional imaging - whole body planar scans
Study NCT04069429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: esophagogastroduodenoscopy with tissue biopsies
Study NCT03974100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GP2411
Description: 60 mg /mL subcutaneous injection every 6 months
Study NCT03974100 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-Prolia (EU-authorized Prolia®)
Description: 60 mg /mL subcutaneous injection every 6 months
Study NCT04522583 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of Myocardial Ischemia
Description: Discharge diagnosis of myocardial ischemia
Study NCT06192719 — intervention group
Intervention type: OTHER
Intervention: None, observational study.
Description: Epidemiological, clinical and dietary data will be collected along with blood, saliva, urine, bile, feces and gallbladder tissue samples.
Study NCT01793298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASM-024
Description: Ascending doses of ASM-024
Study NCT00114543 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aggressive Phototherapy 501-750g
Description: Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-14.
Study NCT00114543 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aggressive Phototherapy 751-1000g
Description: Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-7, and started, stopped, and/or restarted when levels reach 7 mg/dl during days of life 8-14.
Study NCT00114543 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Phototherapy 501-750g
Description: Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥8.0 mg/dl during days of life 1-14.
Study NCT00114543 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Phototherapy 751-1000g
Description: Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥10.0 mg/dl during days of life 1-14.
Study NCT00920699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CoQ10
Description: Capsules containing 300 mg of CoQ10 or matching placebo taken orally twice a day. All participant will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
Study NCT02564718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venous thromboembolism (VTE) with 20 mg once daily.
Study NCT00953862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: In Phase II, atomoxetine was dispensed beginning at 25 mg/day. Dose was adjusted based on clinical response and tolerability over a 4-week period up to 120mg/day and held constant at the optimized level for the final 6 weeks of the trial.
Study NCT01723007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplement
Description: The arms were assigned to receive the supplements and followed for 10 weeks. Every two weeks, the women returned to the clinic for evaluation biochemical, haemogram, anthropometric, bioimpedance, blood pressure and dietary. Weekly, returned to receive the supplements in a sealed box. They received guidance not to disclose what food were receiving the service if he found other women who also participated in the study.
Study NCT01723007 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplement
Description: The arms were assigned to receive the supplements and followed for 10 weeks. Every two weeks, the women returned to the clinic for evaluation biochemical, haemogram, anthropometric, bioimpedance, blood pressure and dietary. Weekly, returned to receive the supplements in a sealed box. They received guidance not to disclose what food were receiving the service if he found other women who also participated in the study.
Study NCT01222702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadazolid
Description: Cadazolid, provided as powder (250 mg, 500 mg or 1000 mg) to be reconstituted as a suspension prior to oral administration
Study NCT01222702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin, provided as capsules (125 mg) for oral administration
Study NCT01222702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-matching cadazolid
Description: Placebo of cadazolid powder for oral suspension
Study NCT01222702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching vancomycin
Description: Placebo of vancomycin capsules
Study NCT02287883 — intervention group
Intervention type: OTHER
Intervention: Observational: Patient Activation and Engagement (PAE)
Description: Observational: Patients receive care from clinics with either low or high levels of patient activation and engagement activities.
Study NCT01744756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: One subconjunctival aplication of Bevacizumabe 0,5ml
Study NCT00614588 — intervention group
Intervention type: DEVICE
Intervention: Body temperature thermometers
Description: Temperature readings every 30 minutes during and post surgery using internal stethoscope, catheter and adhesive patches/electronic thermometer.
Study NCT01335321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylan GF-20 alone
Description: A intraarticular injection of 6ml of Hylan GF-20 (Synvisc)
Study NCT01335321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: A Intraarticular injection of 6ml of Hylan GF-20 (Synvisc) + 1ml of triamcinolone (Triancil)
Study NCT02957162 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Study NCT02957162 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: 3-5 mls of blood is taken at baseline and 3 subsequent timepoints and processed for Endothelial Progenitor Count (EPC).
Study NCT04723732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrrh mouthwash
Description: 1% mouthwash solution of commiphora myrrha, made from Commiphora Myrrha resin extract.
Study NCT04723732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: 0.2% mouthwash solution of chlorhexidine gluconate.
Study NCT04723732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.9% solution of sodium chloride, containing 9 g/L Sodium Chloride (154 mEq/L sodium and 154 mEq/L chloride)
Study NCT00751205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid
Description: Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. In addition, subjects will receive Acetyl-L-Carnitine (ALC) 1000 mg tid. Treatment with Sagopilone and ALC will be continued as long as there is benefit. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
Study NCT00751205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid
Description: Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. Treatment will be continued as long as there is benefit. In addition, subjects will receive 21 weeks of placebo 1000 mg tid. After all patients have completed 6 cycles of treatment, an analysis will be performed to see whether ALC was better than placebo. If this is the case, patients still under placebo treatment will be offered to switch to ALC. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
Study NCT03134547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose sevoflurane group
Description: low volume volatile anesthetics (1.0%)
Study NCT03134547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose sevoflurane group
Description: high volume volatile anesthetics (2.5%)
Study NCT01978236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg
Description: Dabrafenib will be provided for oral administration as 50 mg and 75 mg capsules. Dabrafenib will be dosed orally with approximately 200 mL of water, twice a day. Dabrafenib should be administered under fasting conditions.
Study NCT01978236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib 2.0 mg
Description: Trametinib study treatment will be provided as 0.5 mg and 2.0 mg tablets. should be taken orally with approximately 200 mL of water under fasting conditions, either one hour before or two hours after a meal.